Australia markets close in 4 hours 48 minutes

Acumen Pharmaceuticals, Inc. (ABOS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.8400+0.1900 (+5.21%)
At close: 04:00PM EDT
3.7100 -0.13 (-3.39%)
After hours: 06:29PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.6500
Open3.6900
Bid3.8100 x 400
Ask3.8600 x 500
Day's range3.6450 - 3.9200
52-week range1.8100 - 11.3100
Volume141,601
Avg. volume306,077
Market cap230.706M
Beta (5Y monthly)0.19
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

    Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in May 2024Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024Cash, cash equivalents and marketable securities of $296.6 million as of Mar. 31, 2024, expected to support current clinical and operational activities into the first half of 2027Company to host conference call and webcast today at 8:00 a.m. ET CHAR

  • GlobeNewswire

    Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

    CHARLOTTESVILLE, Va., May 13, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Conference on Monday, May 20, 2024, at 12:30 p.m. ET. The live webcast may be accessed under the Investors tab on www.acu

  • GlobeNewswire

    Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

    CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024, at 8:55 a.m. PT (11:55 a.m. ET). The live webcast may be accessed under the Investors ta